Twilight Litaka Pharma Ltd has been delisted from the stock exchange.
Sector
PharmaceuticalsOpen
₹4.45Prev. Close
₹4.25Turnover(Lac.)
₹0.37Day's High
₹4.45Day's Low
₹4.1552 Week's High
₹052 Week's Low
₹0Book Value
₹-59.61Face Value
₹5Mkt Cap (₹ Cr.)
10.53P/E
0EPS
0Divi. Yield
0No Record Found
No Record Found
| Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Equity Capital | 12.39 | 12.39 | 12.39 | 18.17 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -133.3 | 6.29 | 169.03 | 136.89 |
Net Worth | -120.91 | 18.68 | 181.42 | 155.06 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Revenue | 31.5 | 337.49 | 730.18 | 657.34 |
yoy growth (%) | -90.66 | -53.77 | 11.08 | |
Raw materials | -19.89 | -296.54 | -561.8 | -505.86 |
As % of sales | 63.15 | 87.86 | 76.94 | 76.95 |
Employee costs | -4.81 | -10.12 | -19.98 | -17.67 |
| Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Profit before tax | -14.12 | -48.32 | 19.47 | 63.38 |
Depreciation | -4.97 | -6.4 | -5.1 | -3.64 |
Tax paid | 0 | 0 | -0.92 | -13.93 |
Working capital | -120.21 | -141.58 | 55.95 | |
Other operating items |
| Y/e 31 Mar | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -90.66 | -53.77 | 11.08 | |
Op profit growth | -78.72 | -160 | -30.14 | |
EBIT growth | -71.02 | -173.41 | -33.96 | |
Net profit growth | -13.13 | -4,712.22 | -92.88 |
| Particulars (Rupees in Crores.) | Jun-2014 | Mar-2012 | Mar-2011 |
|---|---|---|---|
Gross Sales | 31.5 | 732.55 | 670.83 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 31.5 | 732.55 | 670.83 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 0 | 1.11 | 3.25 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,840.8 | 147.19 | 4,41,789.55 | 608.7 | 0.87 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 6,753 | 67.4 | 1,79,450.12 | 756 | 0.44 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,452.1 | 68.94 | 1,54,733.87 | 467 | 0 | 2,677 | 249.73 |
Cipla Ltd CIPLA | 1,417.5 | 30.86 | 1,14,182.61 | 384.64 | 0.92 | 3,840.92 | 423.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,327.9 | 34.53 | 1,11,184.65 | -219.4 | 0.6 | 3,802.6 | 375.78 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman
R C Bora
Managing Director
Gopal Ramourti
Executive Director & Chief Financial Officer
N R Bora
Director
A S Chandvankar
Director
M S Raghavan Ayyangar
B-22 H Block,
MIDC Pimpri,
Maharashtra - 411018
Tel: -
Website: -
Email: -
Samhita Complex,
Plot No 13 AB, Saki Naka Andheri(E),
Mumbai-400072
Tel: 91-22-67720300/400
Website: www.shareproservices.com
Email: sharepro@shareproservices.com
Summary
Incorporated as a private limited company in Jan.74, Li Taka Pharmaceuticals was converted into a public limited company in Dec.85. Li Taka Laboratories Pvt Ltd was amalgamated with the company in 198...
Read More
Reports by Twilight Litaka Pharma Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.